Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia

Peter Wnukowski-Mtonga; Sanjay Jayasinghe; Clayton Chiu; Kristine Macartney; Julia Brotherton; Basil Donovan; Madeline Hall; David W Smith; Karen Peterson; Sue Campbell-Lloyd; Christine Selvey; Michelle Giles; John Kaldor; Helen Marshall; Australian Technical Advisory Group on Immunisation (ATAGI)

doi:10.33321/cdi.2020.44.33

Scientific evidence supporting recommendations on the use of the 9-valent HPV vaccine in a 2-dose vaccine schedule in Australia

Commun Dis Intell (2018). 2020 Apr 15:44. doi: 10.33321/cdi.2020.44.33.

Authors

Affiliations

¹ National Centre for Immunisation Research and Surveillance, Westmead, New South Wales.
² National Centre for Immunisation Research and Surveillance and Discipline of Child and Adolescent Health, The Children's Hospital at Westmead Clinical School, University of Sydney, Sydney, New South Wales.
³ Victorian Cytology Service Population Health, VCS Foundation and School of Population and Global Health, University of Melbourne, Melbourne, Victoria.
⁴ The Kirby Institute, University of New South Wales and Sydney Sexual Health Centre, Sydney Hospital, Sydney, New South Wales.
⁵ Royal Brisbane and Women's Hospital, Queensland Health, Brisbane, Queensland.
⁶ Department of Microbiology, PathWest Laboratory Medicine WA and Faculty of Health and Medical Sciences, University of Western Australia, Nedlands, Western Australia.
⁷ Immunisation Program, Queensland Health, Brisbane, Queensland.
⁸ Immunisation Unit, Communicable Diseases Branch, Health Protection NSW, NSW Health, Sydney, New South Wales.
⁹ Communicable Diseases Branch, Health Protection NSW, NSW Health, Sydney, New South Wales.
¹⁰ The Alfred Hospital and Department of Obstetrics and Gynaecology, Monash University, Melbourne, Victoria.
¹¹ The Kirby Institute, University of New South Wales, Sydney, New South Wales.
¹² Vaccinology and Immunology Research Trials Unit, Women's and Children's Hospital and Robinson Research Institute and Adelaide Medical School, University of Adelaide, North Adelaide, South Australia.

PMID: 32299331
DOI: 10.33321/cdi.2020.44.33

Abstract

The Australian Technical Advisory Group on Immunisation (ATAGI) updated recommendations on the use of human papillomavirus (HPV) vaccines in the Australian Immunisation Handbook in 2018, regarding the use of the recently available 9-valent (9vHPV) vaccine, Gardasil 9, and a 2-dose schedule for young adolescents for HPV vaccines. This report provides an overview of the relevant scientific evidence that underpinned these updated recommendations. The 9vHPV vaccine includes 5 HPV types (HPV 31, 33, 45, 52 and 58) additional to the 4 that are also covered by the 4vHPV (Gardasil) vaccine (HPV 6,11,16,18). Accordingly, the 9vHPV vaccine is expected to prevent an additional 15% of cervical cancers and up to 20% of other HPV-related cancers. Non-inferior antibody responses after two 9vHPV vaccine doses given 6-12 months apart in girls and boys aged 9-14 years compared to women aged 16-26 years after three doses support the 2-dose schedule for adolescents of this age group. In clinical trials 9vHPV vaccine was well-tolerated with a similar safety profile to 4vHPV vaccine. The switch to 9vHPV vaccine and a 2-dose schedule is anticipated to improve public acceptability of the program and reduce HPV-related disease in the long-term.

Keywords: Cervical cancer; HPV vaccine; Human papilloma virus; Vaccine schedule; genital warts.

MeSH terms

Adolescent
Adult
Australia / epidemiology
Female
Humans
Immunization Schedule*
Immunogenicity, Vaccine
Male
Papillomavirus Infections / epidemiology
Papillomavirus Infections / prevention & control*
Papillomavirus Vaccines / administration & dosage
Papillomavirus Vaccines / immunology*
Practice Guidelines as Topic
Young Adult

Substances

Papillomavirus Vaccines